FDA Expands Tzield Use to Young Children, Marking Shift in Type 1 Diabetes Care

The U.S. Food and Drug Administration (FDA) has approved an important expansion for Tzield (teplizumab-mzwv), a first-in-class therapy designed to delay the onset of clinical Type 1 diabetes. The therapy can now be used in children as young as 1 year old who have Stage 2 Type 1 diabetes, significantly broadening access for families facing early risk of the disease.

Type 1 diabetes is a progressive autoimmune condition in which the body attacks insulin-producing cells in the pancreas. The disease develops in stages, beginning long before symptoms appear. In Stage 2, children already show immune system activity and abnormal blood sugar levels, even though they may feel completely well. Without intervention, many will progress to Stage 3, when symptoms such as excessive thirst, frequent urination, fatigue and weight loss begin — and lifelong insulin therapy becomes necessary.

Tzield works by targeting the immune system earlier in the disease process. As a CD3-directed monoclonal antibody, it is designed to slow the autoimmune attack, preserving insulin-producing cells and delaying progression to symptomatic disease.

The FDA’s decision was supported by findings from the PETITE-T1D study, which evaluated the therapy in children under age 8. While the study was relatively small and focused on safety, results showed that the treatment’s safety profile in younger children was consistent with what has been observed in older patients. The therapy is given as a once-daily intravenous infusion over 14 consecutive days.

For families, this approval represents something Rachael Sood, NP-C, founder of The Diabetes Collective, calls a “gift of time.” Delaying the onset of Stage 3 diabetes, even by a few years, can make a meaningful difference, particularly during early childhood, when managing insulin therapy can be especially complex.

According to Sood, that additional time can be transformative — not only medically, but educationally and emotionally. She emphasized that managing diabetes is not just about treatment, but about preparation. Families must learn how to navigate blood sugar monitoring, medications and daily decision-making, often in coordination with a wide support network that includes schools, caregivers and community members.

Sood also highlighted the importance of awareness and early identification. She expressed hope for broader screening practices, particularly for children with a family history of diabetes or other autoimmune conditions. Earlier identification of at-risk individuals could allow more families to benefit from therapies like Tzield before symptoms begin.

This approval reflects a broader shift in Type 1 diabetes care: moving from reactive treatment to proactive intervention. Instead of waiting for symptoms to appear, clinicians now have a tool that may delay disease progression during a critical window of development.

While Tzield is not a cure, it represents a meaningful step forward. For patients and families, it offers not just time — but the opportunity to prepare, plan and potentially improve long-term outcomes in a disease that has traditionally been diagnosed only after symptoms appear.